 | ||||||||||||
| ||||||||||||
| ||||||||||||
| ||||||||||||
 | ||||||||||||
 | ||||||||||||
 | ||||||||||||
| ||||||||||
|
|
In-licensing has and will continue to play a vital role in Hana Biosciences mission of Strengthening the Foundation of Cancer Care. Each of Hana’s four clinical compounds were acquired through in-licensing. We feel that innovative science has no boundries; therefore, we believe the combination of external scientific expertise with our internal clinical development capabilities will result in innovative cancer medicines.We are continually looking for the next great scientific innovation that, when combine with our clinical development expertise, can be moved forward through the various stages of drug development. Specifically, we are interested in reviewing opportunities in the following areas: Oncology Tumor Types Hematologic malignancies (leukemias, lymphomas) Solid tumors Melanomas Overall cancer/coagulation cascade Oncology Supportive Care Mucositis Novel supportive care Stage of development Near IND ready or beyond Rights Minimum of US rights available Please direct Business Development inquiries to: Gradon Knotts, Vice President, Business Development Hana Biosciences, Inc. 7000 Shoreline Court, Suite 370 South San Francisco, CA 94080 Phone: 650-228-2769 Fax: 650-588-2787 e-mail: gradon.knotts@hanabiosciences.com |
||||||||
| ||||||||||
| ||||||||||
